<DOC>
	<DOCNO>NCT02098616</DOCNO>
	<brief_summary>The purpose study determine whether treatment Daclatasvir/Asunaprevir/BMS-791325 , without ribavirin , 8 , 6 , 4 week feasible treatment genotype 1a chronic hepatitis C patient without cirrhosis .</brief_summary>
	<brief_title>Rapid Hepatitis C Elimination Trial- A Pilot Study Daclatasvir/Asunaprevir/BMS-791325 With Without Ribavirin To Treat Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Subjects chronically infect HCV genotype 1a HCV RNA ≥ 10,000 IU/mL screen Treatmentnaïve subject previous exposure interferon formulation ( ie , IFNα , pegIFNα ) , ribavirin ( RBV ) , HCV direct act antiviral ( DAA ; protease , polymerase inhibitor , etc . ) Evidence cirrhosis Liver organ transplant Current known history cancer within 5 year prior enrollment Documented suspect hepatocellular carcinoma ( HCC ) Not eligible sofosbuvir + pegylated interferon + ribavirin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Drug Resistance , Viral</keyword>
</DOC>